Optimi Health SEC Filings

Optimi Health Corp. filed a Form 6-K highlighting the completion of its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5mg capsules made at its GMP facility in Princeton, British Columbia.

The capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression, showing that Optimi is leveraging an existing commercial product for research use. Manufacturing and export were conducted under Health Canada’s Drug Establishment Licence framework and required export authorization from Health Canada and import authorization from the UK Home Office.

By supplying both biomass and finished drug product from a single licensed, GMP-compliant site, Optimi presents itself as a vertically integrated supplier of psilocybin and MDMA products for regulated mental health therapies and clinical research markets internationally.

Optimi Health Corp. reported progress on its ibogaine initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company plans to begin finished drug product development this summer at its GMP facility in British Columbia, initially targeting encapsulated 50mg and 100mg doses.

The update follows an April 2026 U.S. executive order that prioritized ibogaine and other psychedelic therapies for accelerated FDA review and expanded patient access, increasing demand for reliable GMP-grade supply. In Canada, ibogaine is regulated as a prescription drug rather than a controlled substance, which, combined with Optimi’s existing Health Canada licenses, positions the company to manufacture and supply ibogaine for research and regulated access.

Optimi already produces validated MDMA and botanical psilocybin products and supplies active ingredients and finished dosages to international clinical and therapeutic programs, including Australia’s Authorized Prescriber Scheme and Canada’s Special Access Program.

Optimi Health Corp. completed a GMP production run of its 5mg psilocybin capsules, the same formulation already prescribed in Australia for treatment-resistant depression. Some of this batch will support upcoming clinical research in the United States and clinical trials in Europe across multiple indications.

The company carried out all stages of manufacturing in-house at its Health Canada Drug Establishment Licence facility in British Columbia, from biomass cultivation and API extraction to encapsulation and packaging. Optimi is authorized to hold substantial quantities of psilocybin and biomass on site, positioning it as a vertically integrated supplier of regulated psychedelic drug products.

Optimi already supplies psilocybin and MDMA products to regulated markets, including patient prescriptions in Australia under the Authorized Prescriber Scheme and access in Canada through the Special Access Program, supporting both current patient use and ongoing clinical research.

Optimi Health Corp. reports deeper losses and liquidity pressure in its six-month results to March 31, 2026, while positioning itself as a GMP psychedelic drug manufacturer with access to international markets. Revenue from drug product sales was $99,500, but expenses of $3.24 million and limited interest income led to a net loss of $3,145,846, widening from $1,455,346 a year earlier. Cash and cash equivalents fell to $106,711, and current liabilities climbed to $9,828,019, producing a significant working capital deficit.

The company operates two 10,000-square-foot facilities in Princeton, British Columbia and holds a Health Canada Drug Establishment Licence, Dealer’s Licence and Precursor Licence, enabling GMP production and export of MDMA and psilocybin, including supply to Australia’s Authorised Prescriber Scheme through a long-term Mind Medicine Australia distribution agreement. Operations remain heavily loss-making, with notable costs in amortization, consulting, wages, investor relations and interest on loans and related-party convertible debentures.

Subsequent to March 31, 2026, Optimi completed a Nasdaq Capital Market public offering of 2,400,000 common shares (symbol “OPTH”), raising approximately CAD$18.4 million in net proceeds after a 1-for-30 reverse stock split. Management highlights both historical dependence on equity and debt financing and the presence of material uncertainties around ongoing liquidity in the MD&A, while the financial statement notes point to improved funding and the ability to meet obligations for at least twelve months following the interim period.

Optimi Health Corp. reports on updated rules in Australia that expand access to psychedelic-assisted therapy using prescribed MDMA and psilocybin. The Therapeutic Goods Administration’s revised Authorized Prescriber framework broadens therapist eligibility, allows treatment in more medically supervised settings, and is intended to support scaling of commercial programs.

Aggregated data show no serious adverse events reported under the scheme since December 2025, reinforcing the real-world safety profile. Reimbursement now spans public programs such as DVA, NDIS and WorkCover, as well as private insurance via Medibank. Optimi, which manufactures GMP-grade MDMA and psilocybin in Canada, highlights its ability to supply these regulated therapies to Australian patients.

Optimi Health Corp. Schedule 13G reports that YA II PN, Ltd. and affiliated entities collectively beneficially own 400,000 shares of common stock, equal to 7.1% of the class. The filing lists shared voting and dispositive power over 400,000 shares and identifies related entities and Mark Angelo as the decisionmaker.

The filing names YA Global Investments II (U.S.), Yorkville Advisors Global, Yorkville Advisors Global II, LLC, YAII GP, YAII GP II, LLC, SC-Sigma Global Partners and Mark Angelo as affiliates that may be deemed to beneficially own the same 400,000 shares. Signatures show the filing activity dated in May 2026.